
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
In this study, the authors examine the suitability of 0.45 µm–rated filters to be used as sterilizing and bioburden-reduction filters against significant populations of organisms such as B. diminuta in a wide range of differential pressures.
over 24 years ago
Outsourcing Outlookover 24 years ago
Monitoring Blend Uniformity with Effusivityover 24 years ago
Bush Budget Combats Bioterrorism, Promotes Drug Safetyover 24 years ago
Liposomes: A Review





